hotspot -WSS

hotspot

author：hotspot 2025-09-30 15:22:28 - browse：8777

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Study finds gene variants tied to breast cancer risk in Black women

hotspot

WSS

Reports of telehealth's death have been greatly exaggerated

Eyeing GLP

Reports of telehealth's death have been greatly exaggerated

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Eyeing GLP

Making the case for fair compensation in clinical trials

entertainment

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

What does generative AI mean for health care? We asked experts

FDA poised to publish guidelines for clinical trial diversity

Heart attack and stroke risk calculators need revising

Cue Health, Covid

Continuity nursing helped my family in our darkest PICU moments

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

As demand for Covid shots wanes, Moderna seeks its next success

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Peter Hotez and the public health issue of online harassment

For longer

focus

ASCO eve: Let’s set the table for this year's meeting

Making the case for fair compensation in clinical trials

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Cue Health, Covid

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

For longer

explore

focus

hotspot

Wikipedia